<!-- # COPYRIGHT NOTICE # This file is part of the "Universal Biomedical Skills" project. # Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu> # All Rights Reserved. # # This code is proprietary and confidential. # Unauthorized copying of this file, via any medium is strictly prohibited. # # Provenance: Authenticated by MD BABU MIA -->

---

name: 'armored-cart-design-agent' description: 'AI-powered design of armored CAR-T cells with cytokine/chemokine expression for enhanced solid tumor efficacy, including IL-12, IL-15, IL-18, and IL-7 armoring strategies.' measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes. allowed-tools:

• read_file
• run_shell_command

---

Armored CAR-T Design Agent

The Armored CAR-T Design Agent provides AI-assisted design of next-generation armored CAR-T cells engineered to express cytokines, chemokines, or other enhancing factors. These armored T cells overcome solid tumor challenges including immunosuppressive TME, poor trafficking, and T cell exhaustion, with recent clinical success in lymphoma (IL-18) and ongoing trials with IL-12, IL-15, and IL-7.

When to Use This Skill

• When designing CAR-T cells for solid tumor applications.
• For selecting optimal armoring payloads (cytokines, chemokines).
• To optimize cytokine expression levels and regulation.
• When engineering safety switches for armored constructs.
• For predicting armored CAR-T efficacy and safety profiles.

Core Capabilities

1. Armoring Payload Selection: Choose optimal cytokines for tumor type.

2. Expression Level Optimization: Balance efficacy vs toxicity.

3. Inducible System Design: Engineer regulated expression systems.

4. Safety Switch Integration: Design kill switches and controls.

5. Construct Optimization: Optimize transgene configuration.

6. Efficacy Prediction: Predict enhanced tumor killing.

Armoring Strategies

Cytokine	Mechanism	Clinical Status	Tumor Types
IL-12	Th1 polarization, IFN-gamma	Phase I/II	Solid tumors
IL-15	T/NK persistence	Phase I/II	Hematologic, solid
IL-18	Inflammasome, IFN-gamma	Phase I (promising)	Lymphoma
IL-7	T cell survival	Phase I	Multiple
IL-21	T cell proliferation	Preclinical	Multiple
CCL19/21	T cell trafficking	Preclinical	Solid tumors

Construct Architecture Options

Component	Options	Consideration
Promoter	EF1a, PGK, CAG, NFAT-inducible	Expression level/timing
Signal Peptide	Native, IL-2ss, IgK	Secretion efficiency
Cytokine	Membrane-bound vs secreted	Local vs systemic
Linker	T2A, P2A, IRES	Co-expression efficiency
Kill Switch	iCasp9, HSV-TK, CD20	Safety control
Position	Before/after CAR	Expression balance

Workflow

1. Input: Target tumor type, TME characteristics, CAR design.

2. Payload Selection: Rank armoring strategies for tumor context.

3. Expression Design: Optimize promoter, levels, regulation.

4. Safety Engineering: Add appropriate control switches.

5. Construct Assembly: Generate optimized DNA sequence.

6. Efficacy Prediction: Model enhanced killing and persistence.

7. Output: Optimized armored CAR construct with annotations.

Example Usage

User: "Design an armored CAR-T for pancreatic cancer targeting mesothelin with IL-12 armoring for TME remodeling."

Agent Action:

python3 Skills/Immunology_Vaccines/Armored_CART_Design_Agent/design_armored_cart.py \
    --car_target mesothelin \
    --tumor_type pancreatic \
    --armoring_payload IL-12 \
    --expression_system NFAT_inducible \
    --safety_switch iCasp9 \
    --backbone lentiviral \
    --optimize_codon human \
    --output armored_cart_design/

Output Components

Output	Description	Format
Construct Sequence	Full transgene DNA	.fasta, .gb
Construct Map	Annotated visualization	.png, .pdf
Expression Model	Predicted levels	.json
Safety Analysis	Risk assessment	.json
Manufacturing Guide	Production recommendations	.md
Predicted Efficacy	Tumor killing model	.json

IL-12 Armoring Details

Aspect	Design Choice	Rationale
Configuration	Tethered IL-12 (p70)	Localized, reduced toxicity
Expression	NFAT-inducible	Activation-dependent
Dose	Low-level expression	Safety optimization
Combination	With PD-1 knockout	Enhanced activity

IL-18 Armoring Details

Aspect	Design Choice	Rationale
Configuration	Secreted mature IL-18	Enhanced IFN-gamma
Expression	Constitutive or inducible	Context-dependent
Clinical Results	Lymphoma responses	Validated approach
Combination	With IL-21	Synergistic

IL-15 Armoring Details

Aspect	Design Choice	Rationale
Configuration	Membrane-tethered IL-15/IL-15Ra	Cis-presentation
Expression	Constitutive moderate	Persistence without toxicity
Benefit	Reduced IL-2 dependence	Manufacturing advantage
Safety	Lower CRS risk	Clinical benefit

AI/ML Components

Payload Selection:

• TME profiling to match cytokine needs
• Multi-objective optimization
• Clinical outcome modeling

Expression Optimization:

• Promoter strength prediction
• Codon optimization
• mRNA stability modeling

Safety Prediction:

• CRS/ICANS risk modeling
• Off-tumor activity prediction
• Systemic cytokine levels

Safety Considerations

Risk	Mitigation	Implementation
Cytokine storm	Inducible expression	NFAT promoter
Systemic toxicity	Membrane tethering	Localized effect
Uncontrolled proliferation	Kill switch	iCasp9
On-target off-tumor	Regulatable CAR	Logic gates

Clinical Trials (2025-2026)

Trial	Armoring	Target	Cancer	Status
NCT03721068	IL-18	CD19	Lymphoma	Phase I (positive)
NCT04119024	IL-12	GD2	Neuroblastoma	Phase I
NCT03932565	IL-15/21	CD19	B-ALL	Phase I
Multiple	IL-7/CCL19	Various	Solid	Preclinical

Prerequisites

• Python 3.10+
• Biopython for sequence handling
• CAR design databases
• Codon optimization tools
• Structure prediction (optional)

Related Skills

• CART_Design_Optimizer_Agent - Base CAR optimization
• NK_Cell_Therapy_Agent - NK cell engineering
• Cytokine_Storm_Analysis_Agent - Safety analysis
• TCell_Exhaustion_Analysis_Agent - Exhaustion prevention

Manufacturing Considerations

Aspect	Armored CAR Challenge	Solution
Vector Size	Larger transgene	Optimize construct
Transduction	Lower efficiency	Increase MOI
Expansion	Cytokine effects	Tune expression
Characterization	Complex phenotype	Enhanced QC

Special Considerations

1. Tumor Type Matching: Different tumors need different armoring
2. Expression Timing: Constitutive vs inducible tradeoffs
3. Dose Finding: Balance efficacy vs toxicity
4. Combination: Consider with checkpoint knockout
5. Manufacturing: Larger constructs affect production

Efficacy Enhancement Mechanisms

Mechanism	Cytokine	Effect
Persistence	IL-15, IL-7	Longer survival
TME Remodeling	IL-12	M2→M1, DC activation
Bystander Killing	IL-18	Enhanced IFN-gamma
Trafficking	CCL19/21	T cell recruitment
Anti-exhaustion	IL-21	Stem-like maintenance

Author

AI Group - Biomedical AI Platform

<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->